![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2008 by The National Academy of Sciences of the USA Biophysics NMR structures of two designed proteins with high sequence identity but different fold and function Center for Advanced Research in Biotechnology, University of Maryland Biotechnology Institute, 9600 Gudelsky Drive, Rockville, MD 20850 *To whom correspondence should be addressed. E-mail: orban/at/umbi.umd.edu Edited by David Baker, University of Washington, Seattle, WA, and approved July 22, 2008 Author contributions: P.A., P.N.B., and J.O. designed research; Y.H., Y.C., and P.A. performed research; P.N.B. contributed new reagents/analytic tools; Y.H. and J.O. analyzed data; and J.O. wrote the paper. Received June 17, 2008. Freely available online through the PNAS open access option. Abstract How protein sequence codes for 3D structure remains a fundamental question in biology. One approach to understanding the folding code is to design a pair of proteins with maximal sequence identity but retaining different folds. Therefore, the nonidentities must be responsible for determining which fold topology prevails and constitute a fold-specific folding code. We recently designed two proteins, GA88 and GB88, with 88% sequence identity but different folds and functions [Alexander et al. (2007) Proc Natl Acad Sci USA 104:11963–11968]. Here, we describe the detailed 3D structures of these proteins determined in solution by NMR spectroscopy. Despite a large number of mutations taking the sequence identity level from 16 to 88%, GA88 and GB88 maintain their distinct wild-type 3-α and α/β folds, respectively. To our knowledge, the 3D-structure determination of two monomeric proteins with such high sequence identity but different fold topology is unprecedented. The geometries of the seven nonidentical residues (of 56 total) provide insights into the structural basis for switching between 3-α and α/β conformations. Further mutation of a subset of these nonidentities, guided by the GA88 and GB88 structures, leads to proteins with even higher levels of sequence identity (95%) and different folds. Thus, conformational switching to an alternative monomeric fold of comparable stability can be effected with just a handful of mutations in a small protein. This result has implications for understanding not only the folding code but also the evolution of new folds. Keywords: conformational switching, evolution, folding Understanding the relationship between protein sequence and 3D structure (1) remains the fundamental unresolved problem in structural biology. There are several reasons why the protein folding problem is so difficult. The large number of conformations available to even a short polypeptide chain makes it difficult to calculate which conformation is most preferred. Also, amino acids in a polypeptide sequence contribute to different extents in coding for a particular fold (2–4). Mutations at some positions will have negligible effect on protein stability whereas other residues cannot be altered without resulting in complete unfolding. In this sense, most natural folds can be considered to be only marginally stable. The combination of these factors results in the general observation that many sequences with little or no discernible homology can frequently have the same overall fold, making prediction of 3D structure from sequence highly problematic in such cases. A different way of looking at this problem was posed by Rose and Creamer (5). They suggested that one could gain insights into the folding code by determining the minimum number of amino acids required to specify one fold over another. The basic idea was to design a pair of proteins with maximal sequence identity but retaining their different wild-type folds. The nonidentities between these two amino acid sequences would then be responsible for coding one fold topology over the other and, thus, represent a fold-specific folding code. Several groups responded to this challenge (6–10) and the most successful of these studies resulted in a protein pair that had 80% sequence identity (11). Some of these proteins were characterized by circular dichroism (CD) spectroscopy under acidic conditions but had a propensity to aggregate near neutral pH. Further, solubility was limited and detailed 3D structures were not determined. Other groups were not able to obtain protein pairs with sequence identities >50% that were sufficiently stable and soluble for detailed structural studies. The tendency to aggregate is perhaps not surprising because it is well known that multimerization can accompany conformational switching and in fact can drive the change from one folded state to another (12–14). We recently described the design and preliminary characterization of two small proteins, GA88 and GB88, with 88% sequence identity but different monomeric folds and functions (15). Here, we present their high-resolution 3D structures determined in solution by using NMR spectroscopy. We show that, despite a large number of mutations taking the sequence identity level from 16% to 88% (Fig. 1
In previous articles, we have referred to these protein pairs as “homologous.” In evolutionary biology, this word implies that the sequence similarity was inherited from a common ancestor of the two proteins. To avoid confusion, we refer to these protein pairs as having “high sequence identity” in this article. Results and Discussion Protein Design. The design process is described in detail in ref. 15, and the made mutations are summarized in Fig. 1 NMR Assignment and Structure of GA88. GA88 was shown to be monomeric based on elution through G25 and G75 gel filtration columns. Linewidths in NMR spectra were also consistent with a monomeric state. 15N HSQC spectra were recorded over a range of temperatures from 2 to 30°C to determine the optimum conditions for data collection with no evidence for exchange broadening of amide resonances. All main-chain signals were assigned and extensive assignments were also made for side-chain resonances. Chemical shift index (24) and NOE data analysis indicated that GA88 contains three α-helices, α1 from residues 9–23, α2 from residues 27–34, and α3 from residues 39–51. These helices pack against each other such that α2 is antiparallel to both α1 and α3 with relatively short three- and four-residue loops connecting the α1–α2 and α2–α3 helices, respectively. The N-terminal residues 1–8 are disordered with sparse interresidue NOEs in this region. Similarly the C-terminal residues 54–56 are not well defined. The average backbone rmsd for the structured region of the polypeptide chain (residues 9–53) is 0.24 ± 0.06 Å with the loops less well defined than the helices. The complete structure statistics for GA88 are summarized in Table 1, and the ensemble of 20 final calculated structures based on experimental data are shown in Fig. 2
The hydrophobic core of GA88 contains residues K13, A16, and L20 from α1, I33 from α2, and V42, K46, and I49 from α3. These are all well ordered in the ensemble with average heavy atom rmsds to the mean structure of 0.36 ± 0.10 Å. The aliphatic side chains of K13 and K46 contribute to packing of the hydrophobic core whereas their ammonium groups are solvent exposed. Additionally, the ε-ammonium group of K13 is proximal to the main-chain carbonyl groups of I33 and A34 in α2, providing a likely C-terminal capping interaction that stabilizes the α2-helix. Similarly, the side-chain ammonium group of K46 is adjacent to the acidic groups of E15 and E19 in α1, thereby further stabilizing the interaction between α3 and α1. A network of adjacent acidic and basic residues is present in this highly charged region of the structure and also includes K10, E14, K18, D22, and D47. Some boundary residues between the core and surface are also ordered in the ensemble including A12, E19, A23, A26, L32, and L50. At the C terminus of the α3-helix, F52 is partially ordered (heavy atom rmsd 0.83 ± 0.56 Å) and forms stabilizing hydrophobic interactions with I25 in the adjacent α1–α2 loop and I49 in the α3-helix (Fig. 3
NMR Assignment and Structure of GB88. GB88 was found to be monomeric based on its mobility during size-exclusion gel chromatography. 15N HSQC spectra recorded over the temperature range 2–25°C indicated no exchange broadening of amide resonances and backbone and side-chain resonance assignments were made at 22°C. The NMR backbone chemical shift data indicated that GB88 contains four β-strands and one α-helix with the secondary structures arranged in the order β1–β2–α–β3–β4. Detailed NOE analysis showed that the β-strands form a four-stranded β-sheet with β1 (residues 1–8) and β4 (residues 51–55) as the central strands in a parallel arrangement and β2 (residues 13–20) and β3 (residues 42–46) as the outer strands, antiparallel to β1 and β4, respectively. The α-helix (residues 23–36) runs diagonally across the sheet and is connected to β2 by a two-residue loop and to β3 by a five-residue loop. The main chain is generally well ordered with an average backbone rmsd of 0.52 ± 0.10 Å. The hydrophobic core of GB88 is well defined and consists of residues Y3, L5, and L7 in β1, A26, F30, and A34 in the α-helix, contributions from W43 and Y45 in β3, and F52 and V54 in β4. These residues have average heavy atom rmsds of 0.73 ± 0.17 Å. A number of boundary residues pack against this core providing further stabilizing interactions. These include L9 in β1, K18 and L20 in β2, and E27, Y29, K31, Y33, and T38 in the α-helix. The structure statistics for GB88 are summarized in Table 1 and an overlay of the 20 final structures is shown in Fig. 2 Comparison of GA88 and Parent Structures. A superposition of the GA88 and PSD-1 (25) 3D structures is shown in Fig. 4
Comparison of GB88 and Parent Structures. The design of GB88 involved the introduction of 17 mutations and the impact of these changes was evaluated by comparing its 3D structure with that of the wild-type precursor, GB1 (26). A superposition of GB88 with GB1 is shown in Fig. 4 One of the main observations is that large changes in amino acid size can be incorporated in regions between the core and surface with essentially no effect on the global fold. However, some mutations do lead to local structural differences compared with wild-type GB1. For example, introduction of the G9L, L12A, G14E, and G38T mutations results in side-chain repacking and some changes in backbone conformation in the α–β3 loop and adjacent β1–β2 loop (Fig. 3 Amino Acid Identities. A key question is how can so many identities be tolerated in either the 3-α fold or the α/β fold. Presumably, part of the reason this is possible is because most of the core residues do not overlap in GA88 and GB88. Significantly overlapping core residues would be difficult to repack in alternate folds while maintaining sequence identity. If one considers the identities first, residues that contribute appreciably to the core of GA88 (K13, A16, L20, V42, and K46; Fig. 2
Amino Acid Nonidentities. The geometries of the seven nonidentities in each structure are indicated in Fig. 6
Nonidentical residues that are solvent accessible in either the 3-α or α/β fold and, therefore, have few packing interactions with other amino acids may be mutation tolerant and not have a major role in conformational switching. Solvent accessibility calculations of the GA88 and GB88 structures (Fig. 5 Mutations were made at the following positions based on analysis of the structures: I25T and L50K in GA88, A24G and T49I in GB88. Further mutations were also made at Y33I and L20A in the α/β fold. The latter mutation decreases identity but was made to regain some stability in the α/β fold. The resulting proteins, GA95 and GB95, have 95% sequence identity and are monomeric by gel filtration. The thermal denaturation midpoint is 52.0°C for GA95 and 48.5°C for GB95. The HSQC spectra of these proteins are consistent with the distinct 3-α and α/β folds of the parent proteins (Fig. 7
Thus, the structures of GA88 and GB88 lead to the design of proteins with even higher identities. Only three or fewer amino acids are responsible for shifting the equilibrium from one stable monomeric fold to the other. The remaining three nonidentities are L20, I30, and L45 in GA95 and A20, F30, and Y45 in GB95. The destabilizing effect of an A20L mutation in GB88 has already been discussed above. The I30/F30 residues have similar secondary-structure propensities while F30 is completely buried in the α/β fold and I30 has limited solvent accessibility in the 3-α fold. Given the large number of contacts to these amino acids in both folds, mutation of either may be sufficient to switch conformations or unfold the protein. In contrast, the L45/Y45 residues have similar solvent accessibility but very different secondary-structure propensities. In GA88, L45 is located in the α3-helix and has strong helical and moderate β-strand propensities. In GB88, Y45 is located in the β3-strand and has strong β-strand and relatively weak helical propensities. Therefore, residue 45 may represent a tipping point in the sequences particularly when one considers that the nearest neighbors on either side, WT and KD, have net β-strand and α-helical preferences, respectively. Future studies will address the sequence dependence of conformational switching in these high-sequence identity proteins. Methods Protein Expression and Purification. GA and GB variants were cloned into the vector pG58, which encodes an engineered subtilisin prosequence as an N-terminal fusion domain, and the resulting fusion proteins were purified by using an affinity-cleavage tag system that we developed (30), essentially as described in ref. 15. The system enabled the rapid, standardized purification of mutant proteins, even of low stability. A commercial version of the purification system is available through Bio-Rad Laboratories (Profinity eXact Purification System). Minimal media (31) was used for 15N and 13C labeling. Soluble cell extract of prodomain (eXact tag) fusion protein was injected on a 5-ml S189 column at 5 ml/min to allow binding and then washed with 10 column volumes of 100 mM potassium phosphate, pH 7.2 to remove impurities. To cleave and elute the purified target protein, 6 ml of 10 mM sodium azide, 100 mM potassium phosphate, pH 7.2 was injected at 0.5 ml/min. The purified protein was then concentrated for NMR analysis. NMR Spectroscopy. 15N- and 13C/15N-labeled protein samples were prepared at concentrations in the range of 0.15–0.3 mM in 100 mM potassium phosphate buffer (pH 7.2) containing 10% D2O. NMR spectra were collected on a Bruker AVANCE 600 MHz spectrometer fitted with a z axis gradient 1H/13C/15N triple resonance cryoprobe. NMR spectra of GA88 and GB88 were recorded at 22°C, whereas spectra of GA95 and GB95 were acquired at 20°C. Processing was done by using nmrPipe (32) and spectra were analyzed with Sparky (33). NMR assignments were obtained by using standard triple resonance methods. Backbone resonances were assigned with HNCACB, CBCA(CO)NH, HBHA(CO)NH, and HNCO spectra. Aliphatic side-chain assignments were made by using a combination of (H)C(CO)NH-TOCSY and H(CCO)NH-TOCSY spectra. Aromatic assignments were obtained from 2D CBHD and CBHE experiments and NOESY spectra. Interproton NOEs were derived from 3D 15N NOESY and aliphatic and aromatic 3D 13C NOESY spectra with mixing times of 100 and 150 ms. Structure Calculations and Analysis. Structures were calculated by using CNS 1.1 (34) with standard simulated annealing and torsion dynamics protocols. An extended polypeptide chain was used as the starting point. All prochiral groups were given floating assignments until they could be unambiguously assigned from the structure. An initial set of NOE restraints was generated automatically by using NOEID, an in-house NOE assignment program. Further assignments were obtained in a semiautomated mode by using NOEID and intermediate structures to narrow down ambiguous assignments iteratively. Interproton distance restraints were based on peak intensities and categorized as strong (1.8–3.0 Å), medium (1.8–4.0 Å), weak (1.8–5.0 Å), and very weak (2.8–6.0 Å). Backbone dihedral restraints were obtained from chemical shift data by using TALOS (35). Hydrogen bond restraints, 1.5–2.5 Å for rHN-O and 2.3–3.2 Å for rN-O, were used only in the final stages of refinement. Final values for force constants were 1,000 kcal mol−1Å−2 for bond lengths, 500 kcal mol−1 rad−2 for angles and improper torsions, 40 kcal mol−1Å−2 for experimental distance restraints, 200 kcal mol−1 rad−2 for dihedral angle restraints, and 4.0 kcal mol−1Å−4 for the van der Waals repulsion term. The final ensemble of 20 structures was chosen by using standard criteria including low total energy, no NOE distance violations >0.3 Å, no dihedral angle violations >5°, and other measures of structure quality shown in Table 1. Structures were analyzed by using PROCHECK-NMR (36), QUANTA (Molecular Simulations Inc.), MOLMOL (37), and PyMol (38). Solvent accessible surface areas were calculated with GETAREA (39). Supporting Information
Acknowledgments. This work was supported by National Institutes of Health Grant GM62154 and a grant from the W. M. Keck Foundation. Footnotes The authors declare no conflict of interest. This article is a PNAS Direct Submission. Data deposition: The NMR assignments for GA88 and GB88 have been deposited in BioMagResBank, www.bmrb.wisc.edu (accession no. BMRB-15535 and BMRB-15537, respectively). The coordinates for the GA88 and GB88 structures have been deposited in the Protein Data Bank, www.pdb.org (PDB ID codes 2JWS and 2JWU, respectively). This article contains supporting information online at www.pnas.org/cgi/content/full/0805857105/DCSupplemental. References 1. Anfinsen CB. Principles that govern the folding of protein chains. Science. 1973;181:223–230. [PubMed] 2. Lattman EE, Rose GD. Protein folding - what's the question? Proc Natl Acad Sci USA. 1993;90:439–441. [PubMed] 3. Dahiyat BI, Mayo SL. Probing the role of packing specificity in protein design. Proc Natl Acad Sci USA. 1997;94:10172–10177. [PubMed] 4. Cordes MH, Walsh NP, McKnight CJ, Sauer RT. Evolution of a protein fold in vitro. Science. 1999;284:325–328. [PubMed] 5. Rose GD, Creamer TP. Protein folding: Predicting predicting. Proteins. 1994;19:1–3. [PubMed] 6. Jones DT, et al. Towards meeting the Paracelsus Challenge: The design, synthesis, and characterization of paracelsin-43, an alpha-helical protein with over 50% sequence identity to an all-beta protein. Proteins. 1996;24:502–513. [PubMed] 7. Dalal S, Balasubramanian S, Regan L. Transmuting alpha helices and beta sheets. Fold Des. 1997;2:R71–79. [PubMed] 8. Dalal S, Balasubramanian S, Regan L. Protein alchemy: Changing beta-sheet into alpha-helix. Nat Struct Biol. 1997;4:548–552. [PubMed] 9. Yuan SM, Clarke ND. A hybrid sequence approach to the paracelsus challenge. Proteins. 1998;30:136–143. [PubMed] 10. Blanco FJ, Angrand I, Serrano L. Exploring the conformational properties of the sequence space between two proteins with different folds: An experimental study. J Mol Biol. 1999;285:741–753. [PubMed] 11. Dalal S, Regan L. Understanding the sequence determinants of conformational switching using protein design. Protein Sci. 2000;9:1651–1659. [PubMed] 12. Kirsten FM, Dyda F, Dobrodumov A, Gronenborn AM. Core mutations switch monomeric protein GB1 into an intertwined tetramer. Nat Struct Biol. 2002;9:877–885. [PubMed] 13. Kuloglu ES, McCaslin DR, Markley JL, Volkman BF. Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions. J Biol Chem. 2002;277:17863–17870. [PubMed] 14. Weissmann C. Birth of a prion: Spontaneous generation revisited. Cell. 2005;122:165–168. [PubMed] 15. Alexander PA, He Y, Chen Y, Orban J, Bryan PN. The design and characterization of two proteins with 88% sequence identity but different structure and function. Proc Natl Acad Sci USA. 2007;104:11963–11968. [PubMed] 16. Myhre EB, Kronvall G. Heterogeneity of nonimmune immunoglobulin Fc reactivity among gram-positive cocci: Description of three major types of receptors for human immunoglobulin G. Infect Immun. 1977;17:475–482. [PubMed] 17. Reis KJ, Ayoub EM, Boyle MDP. Streptococcal Fc receptors. II. Comparison of the reactivity of a receptor from a group C streptococcus with staphylococcal protein A. J Immunol. 1984;132:3098–3102. [PubMed] 18. Fahnestock SR, Alexander P, Nagle J, Filpula D. Gene for an immunoglobulin-binding protein from a Group G Streptococcus. J Bacteriol. 1986;167:870–880. [PubMed] 19. Falkenberg C, Bjorck L, Akerstrom B. Localization of the binding site for streptococcal protein G on human serum albumin. Identification of a 5.5-kilodalton protein G binding albumin fragment. Biochemistry. 1992;31:1451–1457. [PubMed] 20. Frick IM, et al. Convergent evolution among immunoglobulin G-binding bacterial proteins. Proc Natl Acad Sci USA. 1992;89:8532–8536. [PubMed] 21. de Chateau M, Bjorck L. Protein PAB, a mosaic albumin-binding bacterial protein representing the first contemporary example of module shuffling. J Biol Chem. 1994;269:12147–12151. [PubMed] 22. de Chateau M, Holst E, Bjorck L. Protein PAB, an albumin-binding bacterial surface protein promoting growth and virulence. J Biol Chem. 1996;271:26609–26615. [PubMed] 23. Rozak DA, et al. Using offset recombinant polymerase chain reaction to identify functional determinants in a common family of bacterial albumin binding domains. Biochemistry. 2006;45:3263–3271. [PubMed] 24. Wishart DS, Sykes BD. The 13C chemical-shift index: A simple method for the identification of protein secondary structure using 13C chemical-shift data. J Biomol NMR. 1994;4:171–180. [PubMed] 25. He Y, et al. Structure, dynamics, and stability variation in bacterial albumin binding modules: Implications for species specificity. Biochemistry. 2006;45:10102–10109. [PubMed] 26. Gallagher TD, Alexander P, Bryan P, Gilliland G. Two crystal structures of the B1 Immunoglobulin-binding domain of Streptococcal Protein G and comparison with NMR. Biochemistry. 1994;33:4721–4729. [PubMed] 27. Munoz V, Serrano L. Intrinsic secondary structure propensities of the amino acids, using statistical phi-psi matrices: Comparison with experimental scales. Proteins. 1994;20:301–311. [PubMed] 28. Street AG, Mayo SL. Intrinsic beta-sheet propensities result from van der Waals interactions between side chains and the local backbone. Proc Natl Acad Sci USA. 1999;96:9074–9076. [PubMed] 29. Serrano L, Neira JL, Sancho J, Fersht AR. Effect of alanine versus glycine in alpha-helices on protein stability. Nature. 1992;356:453–455. [PubMed] 30. Ruan B, Fisher KE, Alexander PA, Doroshko V, Bryan PN. Engineering subtilisin into a fluoride-triggered processing protease useful for one-step protein purification. Biochemistry. 2004;43:14539–14546. [PubMed] 31. Alexander P, Fahnestock S, Lee T, Orban J, Bryan P. Thermodynamic analysis of the folding of the Streptococcal Protein G IgG-binding domains B1 and B2: Why small proteins tend to have high denaturation temperatures. Biochemistry. 1992;31:3597–3603. [PubMed] 32. Delaglio F, et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6:277–293. [PubMed] 33. Goddard TD, Kneller DG. SPARKY. San Francisco: University of California; 2001. Version 3. 34. Brunger AT, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D. 1998;54:905–921. [PubMed] 35. Cornilescu G, Delaglio F, Bax A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR. 1999;13:289–302. [PubMed] 36. Laskowski RA, Rullmann JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8:477–486. [PubMed] 37. Koradi R, Billeter M, Wuthrich K. MOLMOL: A program for display and analysis of macromolecular structures. J Mol Graphics. 1996;14:51–55. 38. DeLano WL. The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific; 2002. 39. Fraczkiewicz R, Braun W. Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. J Comp Chem. 1998;19:319–333. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Science. 1973 Jul 20; 181(96):223-30.
[Science. 1973]Proc Natl Acad Sci U S A. 1993 Jan 15; 90(2):439-41.
[Proc Natl Acad Sci U S A. 1993]Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10172-7.
[Proc Natl Acad Sci U S A. 1997]Science. 1999 Apr 9; 284(5412):325-8.
[Science. 1999]Proteins. 1994 May; 19(1):1-3.
[Proteins. 1994]Proteins. 1996 Apr; 24(4):502-13.
[Proteins. 1996]Fold Des. 1997; 2(5):R71-9.
[Fold Des. 1997]Nat Struct Biol. 1997 Jul; 4(7):548-52.
[Nat Struct Biol. 1997]Proteins. 1998 Feb 1; 30(2):136-43.
[Proteins. 1998]Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):11963-8.
[Proc Natl Acad Sci U S A. 2007]Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):11963-8.
[Proc Natl Acad Sci U S A. 2007]Infect Immun. 1977 Sep; 17(3):475-82.
[Infect Immun. 1977]J Immunol. 1984 Jun; 132(6):3098-102.
[J Immunol. 1984]J Bacteriol. 1986 Sep; 167(3):870-80.
[J Bacteriol. 1986]Biochemistry. 1992 Feb 11; 31(5):1451-7.
[Biochemistry. 1992]J Biomol NMR. 1994 Mar; 4(2):171-80.
[J Biomol NMR. 1994]Biochemistry. 2006 Aug 22; 45(33):10102-9.
[Biochemistry. 2006]Biochemistry. 1994 Apr 19; 33(15):4721-9.
[Biochemistry. 1994]Proteins. 1994 Dec; 20(4):301-11.
[Proteins. 1994]Proc Natl Acad Sci U S A. 1999 Aug 3; 96(16):9074-6.
[Proc Natl Acad Sci U S A. 1999]Nature. 1992 Apr 2; 356(6368):453-5.
[Nature. 1992]Biochemistry. 2004 Nov 23; 43(46):14539-46.
[Biochemistry. 2004]Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):11963-8.
[Proc Natl Acad Sci U S A. 2007]Biochemistry. 1992 Apr 14; 31(14):3597-603.
[Biochemistry. 1992]J Biomol NMR. 1995 Nov; 6(3):277-93.
[J Biomol NMR. 1995]Acta Crystallogr D Biol Crystallogr. 1998 Sep 1; 54(Pt 5):905-21.
[Acta Crystallogr D Biol Crystallogr. 1998]J Biomol NMR. 1999 Mar; 13(3):289-302.
[J Biomol NMR. 1999]J Biomol NMR. 1996 Dec; 8(4):477-86.
[J Biomol NMR. 1996]